

## Novavax COVID-19 Vaccine EXAMPLE Competency Exam

The following questions pertain to the Novavax COVID-19 vaccine (see [EUA](#)):

1. This vaccine is authorized for use in which of the following age groups for the primary series?
  - a. 6 months – 5 years
  - b. 6 – 11 years
  - c. 12 years & older
  - d. 18 years & older
2. The vaccine is given intramuscularly as a series of \_\_\_\_\_.
  - a. 2-doses (0.25mL) at least 3 weeks apart
  - b. 2-doses (0.5mL) at least 3 weeks apart
  - c. 3-doses (0.25mL) at least 8 weeks apart
  - d. Both (a) and (c) are correct
3. **Unpunctured vials can be safely stored under the following conditions:**
  - a. Ultra-cold (-90°C to -60°C) up to the expiration date found on [Novavax's online LOT expiry checker](#)
  - b. Freezer (-50°C to -15°C) for up to the expiration date found on [Novavax's online LOT expiry checker](#)
  - c. Refrigerator (2°C to 8°C) for up to the expiration date found on [Novavax's online LOT expiry checker](#)
  - d. Both (b) & (c) are correct
4. **Patients that have completed a COVID-19 vaccine series with Novavax that are unable or unwilling to receive an mRNA bivalent booster are eligible for a Novavax booster dose in the following situations:**
  - a. ≥12 years of age at least 8 weeks since the last dose in the primary series
  - b. ≥12 years of age at least 6 months since the last dose in the primary series
  - c. ≥18 years of age at least 8 weeks since the last dose in the primary series
  - d. ≥18 years of age at least 6 months since the last dose in the primary series
5. **After the first dose has been drawn, the vial should be stored between \_\_\_\_\_ and discarded after \_\_\_\_\_.**
  - a. -50°C to -15°C; 6 hours
  - b. 2°C to 8°C; 12 hours
  - c. 2°C to 25°C; 6 hours
  - d. 2°C to 25°C; 12 hours
6. **True/False** This vaccine must be diluted prior to administration.
7. **True/False** Before drawing up a dose of the vaccine, vigorously shake the vial to properly mix the product.
8. **True/False** This vaccine contains the SARS-CoV-2 recombinant spike protein and Matrix-M adjuvant using more traditional technologies, making this vaccine an option for individuals that are unvaccinated, especially for those hesitant about getting other available COVID-19 vaccines (i.e., mRNA-based).

---

Vaccine Provider's Printed Name

Signature

Date